ANAHEIM, CA, March 15, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced an update on the pilot program for weight loss with Atlantis Medical Wellness & Weight Loss Center. The weight loss program began in October 2017 and the Company reports that Atlantis has successfully enrolled a total of twelve individuals to date as planned into the program. The initial results have been positive as reported by patients. 

As mentioned in the Company’s previous release, BioCorRx has teamed up with Dr. Benjamin Gonzalez, Medical Director of Atlantis Medical Wellness & Weight Loss Center in Silver Spring, MD. Dr. Gonzalez is renowned for his expertise in clinical nutrition with a focus on exercise nutrition and weight management. 

According to the CDC, more than one-third (36.5%) of U.S. adults have obesity. According to a 2012 article in the Journal of Health Economics, estimates of current healthcare costs of obesity range from $147 billion to nearly $210 billion per year. Some of the risks associated with this disease include heart disease and stroke, high blood pressure, metabolic syndrome, breathing problems and other health issues.

Brady Granier, CEO, President, and Director of BioCorRx, stated, "We are very pleased with the feedback we have received from Dr. Gonzalez and the patients enrolled in the pilot program to date. We anticipated that this program would help individuals struggling with their weight in some way, but it’s great to actually hear the excitement from those enrolled thus far. One of the first patients who enrolled in the program reported a weight loss of 25 pounds after three months along with healthier lifestyle habits. So far, most of the participants polled have expressed reduced cravings for food. We look forward to completing the pilot mid-year and plan to begin marketing the official weight loss program as anticipated immediately thereafter.

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304